US and/or EU available treatment for challenging and/or rare disorders are not all available in the MENA region. In general, multinational companies have little interest in registering these treatments with the local health authorities since patients often lack inadequate financial support.
MECAPHARMA^® endeavors to bring to the region on NPU basis, and to register, any available treatment for patients. The best way to ensure continuity of treatment and patient compliance remains in the registration of treatment related products with the respective MENA health authorities. MECAPHARMA^® fills the gaps between multinational pharmaceutical companies and all patients in MENA suffering from challenging and/or rare disorders.